Pharmaceuticals - Community Register


Community register of veterinary medicinal products


Product information

Invented name: Vectra 3D   
Auth. number : EU/2/13/156
Active substance : dinotefuran, pyriproxyfen, permethrin
ATC: Anatomical main group: QP - Antiparasitic products, insecticides and repellents
Therapeutic subgroup: QP53 - Ectoparaciticides, insecticides and repellents
Pharmacological subgroup: QP53A - Ectoparasiticides for topical use, incl. insecticides
Chemical subgroup: QP53AC - Pyrethrins and pyrethroids
Chemical substance: QP53AC54 - permethrin, combinations
(See WHO ATCvet Index)
Indication: Fleas:
Treatment and prevention of flea infestation (Ctenocephalides felis and Ctenocephalides canis). The treatment prevents flea infestation for one month. It also prevents multiplication of fleas for two months after application by inhibiting egg hatching (ovicidal activity) and by inhibiting the emergence of adults from eggs laid by adult fleas (larvicidal activity).
The veterinary medicinal product can be used as part of a treatment strategy for flea allergy dermatitis (FAD).
The veterinary medicinal product has persistent acaricidal and repellent efficacy against tick infestations (Rhipicephalus sanguineus and Ixodes ricinus for one month, and Dermacentor reticulatus for up to three weeks).
If ticks are present when the veterinary medicinal product is applied, the ticks may not all be killed within the first 48 hours, but they may be killed within a week. To removal ticks it is recommended to use an appropriate tick removal device.
Sand flies, mosquitoes and stable flies:
The treatment provides persistent repellent (anti-feeding) activity. It prevents biting from sand flies (Phlebotomus perniciosus), mosquitoes (Culex pipiens, Aedes aegypti) and from stable flies (Stomoxys calcitrans) for one month post-application. The treatment also provides persistent insecticidal activity for one month against mosquitoes (Aedes aegypti) and stable fly (Stomoxys calcitrans).
Marketing Authorisation Holder: Ceva Santé Animale
10 avenue de la Ballastière, 33500 Libourne, France
EPAR and active package presentations

Package presentations

Information about presentations can be found in the website of the European Medicines Agency under the section "Product Information".
Likewise, presentations on which there has been a Commission decision are referred in the Summary of Product Characteristics (Annex I to the Commission Decision granting the marketing authorisation) which is available in the Community Register.

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
06/12/2013 Centralised - Authorisation EMEA/V/C/2555 (2013)8903 of 04/12/2013
03/11/2014 Corrigendum (2013)8903 cor of 04/12/2013
20/02/2015 Centralised - Variation EMEA/V/C/2555/IA/4/G
Updated with Decision(2016)1318 of 25/02/2016
19/02/2016 Centralised - Variation EMEA/V/C/2555/IB/6
Updated with Decision(2017)1290 of 17/02/2017
29/02/2016 Centralised - Yearly update (2016)1318 of 25/02/2016
21/02/2017 Centralised - Yearly update (2017)1290 of 17/02/2017